174 related articles for article (PubMed ID: 30390643)
21. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.
Tatli Dogan H; Kiran M; Bilgin B; Kiliçarslan A; Sendur MAN; Yalçin B; Ardiçoglu A; Atmaca AF; Gumuskaya B
Diagn Pathol; 2018 Aug; 13(1):60. PubMed ID: 30144808
[TBL] [Abstract][Full Text] [Related]
22. Cancer Stem Cell Niche and Immune-Active Tumor Microenvironment in Testicular Germ Cell Tumors.
Kalavska K; Kucerova L; Schmidtova S; Chovanec M; Mego M
Adv Exp Med Biol; 2020; 1226():111-121. PubMed ID: 32030680
[TBL] [Abstract][Full Text] [Related]
23. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
Berghoff AS; Ricken G; Wilhelm D; Rajky O; Widhalm G; Dieckmann K; Birner P; Bartsch R; Preusser M
J Neurooncol; 2016 Oct; 130(1):19-29. PubMed ID: 27436101
[TBL] [Abstract][Full Text] [Related]
24. Frequent expression of CD45RO memory T cell marker as well as low to high expression of PD-1 and PD-L1 inhibitory molecules in seminoma and dysgerminoma.
Farahani H; Dehghanian AR; Khademolhosseini A; Haghshenas MR; Erfani N
J Reprod Immunol; 2024 Feb; 161():104184. PubMed ID: 38171036
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics.
Karpathiou G; Casteillo F; Giroult JB; Forest F; Fournel P; Monaya A; Froudarakis M; Dumollard JM; Prades JM; Peoc'h M
Oncotarget; 2017 Mar; 8(12):19310-19322. PubMed ID: 28038471
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment.
D'Angelo SP; Shoushtari AN; Agaram NP; Kuk D; Qin LX; Carvajal RD; Dickson MA; Gounder M; Keohan ML; Schwartz GK; Tap WD
Hum Pathol; 2015 Mar; 46(3):357-65. PubMed ID: 25540867
[TBL] [Abstract][Full Text] [Related]
27. Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors.
Xie S; Huang J; Qiao Q; Zang W; Hong S; Tan H; Dong C; Yang Z; Ni L
Cancer Immunol Immunother; 2018 Nov; 67(11):1685-1694. PubMed ID: 30128738
[TBL] [Abstract][Full Text] [Related]
28. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
Tessier-Cloutier B; Kalloger SE; Al-Kandari M; Milne K; Gao D; Nelson BH; Renouf DJ; Sheffield BS; Schaeffer DF
BMC Cancer; 2017 Sep; 17(1):618. PubMed ID: 28870260
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D
Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013
[TBL] [Abstract][Full Text] [Related]
30. T-lymphocyte profiles differ between keratoacanthomas and invasive squamous cell carcinomas of the human skin.
Bauer C; Abdul Pari AA; Umansky V; Utikal J; Boukamp P; Augustin HG; Goerdt S; Géraud C; Felcht M
Cancer Immunol Immunother; 2018 Jul; 67(7):1147-1157. PubMed ID: 29799076
[TBL] [Abstract][Full Text] [Related]
31. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
32. Is the Wnt/β catenin signalling pathway activated in Seminoma?: An immunohistochemical study.
Fernando G; Paul F; Laura J; Alejandra AM; Gabriela M; Alberto PL
J Cancer Res Ther; 2016; 12(2):1075-9. PubMed ID: 27461702
[TBL] [Abstract][Full Text] [Related]
33. Systemic immune-inflammation index in germ-cell tumours: search for a biological prognostic biomarker.
Albany C
Br J Cancer; 2018 Mar; 118(6):761-762. PubMed ID: 29485981
[TBL] [Abstract][Full Text] [Related]
34. Tumor-infiltrating lymphocytes are associated with β-catenin overexpression in breast cancer.
Ma X; Zhao X; Yan W; Yang J; Zhao X; Zhang H; Hui Y; Zhang S
Cancer Biomark; 2018 Feb; 21(3):639-650. PubMed ID: 29286921
[TBL] [Abstract][Full Text] [Related]
35. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort.
Ness N; Andersen S; Khanehkenari MR; Nordbakken CV; Valkov A; Paulsen EE; Nordby Y; Bremnes RM; Donnem T; Busund LT; Richardsen E
Oncotarget; 2017 Apr; 8(16):26789-26801. PubMed ID: 28460462
[TBL] [Abstract][Full Text] [Related]
36. Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers.
Green AR; Aleskandarany MA; Ali R; Hodgson EG; Atabani S; De Souza K; Rakha EA; Ellis IO; Madhusudan S
Cancer Immunol Res; 2017 Apr; 5(4):292-299. PubMed ID: 28254786
[TBL] [Abstract][Full Text] [Related]
37. Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy.
Fankhauser CD; Sander S; Roth L; Gross O; Eberli D; Sulser T; Seifert B; Beyer J; Hermanns T
Br J Cancer; 2018 Mar; 118(6):825-830. PubMed ID: 29485982
[TBL] [Abstract][Full Text] [Related]
38. Prediction of relapse in stage I testicular germ cell tumor patients on surveillance: investigation of biomarkers.
Lobo J; Gillis AJM; van den Berg A; Looijenga LHJ
BMC Cancer; 2020 Aug; 20(1):728. PubMed ID: 32758242
[TBL] [Abstract][Full Text] [Related]
39. Glypican 3: a novel marker in testicular germ cell tumors.
Zynger DL; Dimov ND; Luan C; Teh BT; Yang XJ
Am J Surg Pathol; 2006 Dec; 30(12):1570-5. PubMed ID: 17122513
[TBL] [Abstract][Full Text] [Related]
40. Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas: comparison between primary tumors and metastases.
Dislich B; Stein A; Seiler CA; Kröll D; Berezowska S; Zlobec I; Galvan J; Slotta-Huspenina J; Walch A; Langer R
Cancer Immunol Immunother; 2017 Jun; 66(6):777-786. PubMed ID: 28289861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]